论文部分内容阅读
泌尿学杂志11月报道了由University Hospital of Cleveland的Dr.Michael G.Oefelein和他的同事们研究的关于“长期接受雄激素抑制剂治疗前列腺癌患者可导致骨折的危险性增加”的文章,对接受雄激素抑制剂治疗的181位前列腺癌患者进行了42到51个月的连续观察。 结果发现181位男性中有9位发生了骨折。在70岁以上的健康男性中,骨折的发生率为1％,而服用雄激素抑制剂的人骨折奇数比为4.97。其中5人的骨折发生在髋部。65岁以上的正常男性髋部骨折发生率为5/1000,
The Journal of Urology reported in November on “The Increased Risk of Fracture Can Lead to Prostate Cancer in Patients Undergoing Long-term Administration with Androgen Inhibitors” by Dr. Michael G. Oefelein and colleagues at the University Hospital of Cleveland, 181 prostate cancer patients treated with androgen inhibitor were observed continuously for 42 to 51 months. Nine out of 181 men were found to have fractures. In healthy men over the age of 70, the incidence of fractures was 1%, while the odds ratio for people with androgen depressants was 4.97. Five of the fractures occurred in the hip. The incidence of hip fracture in normal men over the age of 65 was 5/1000,